

Corporate Presentation

A prospective integrated cannabis company



Disclaimer

Caution on Forward-Looking Statements

This presentation contains "forward-looking information" which may include, but is not limited to, statements with respect to the future financial or operating performances of Capital Mining Limited ("CMY") and its proposed acquisitions, the future price of proposed products, the timing and extent of estimated future production, costs of production, capital and operating expenditures, costs and timing of the development of any expansion, requirements for additional capital, Canadian and US legislative requirements, the timing or likelihood or any legislative changes which may allow the distribution or sale or cannabis products, limitations of insurance coverage and regulatory matters. Often, but not always, forward-looking information statements can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", or "believes", or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might", or "will" be taken, occur or be achieved.

Forward-looking statements involve both known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of CMY and/or its proposed subsidiaries to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Although CMY has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.

This presentation contains information, ideas and analysis which are proprietary to CMY. By agreeing to receive this information you also agree to respect the confidential nature of the information, ideas and analysis and of this presentation.

Important Information

This presentation is not an offer, invitation or recommendation to subscribe for, or purchase securities by CMY. Nor does this presentation constitute investment or financial product advice (nor tax, accounting or legal advice) and is not intended to be used for the basis of making an investment decision. Investors should obtain their own advice before making any investment decision. By reviewing or retaining this presentation, you acknowledge and represent that you have read, understood and accepted the terms of this important notice.



Investment Overview



Capital Mining Snapshot

ASX: CMY

Market Cap: AUD\$7.97 million (at 20 March 2015)

Share price: AUD\$0.006

Shares on Issue: 1,329,156,618 fully paid ordinary shares

Options: 269,336,524 listed options exercisable AUD\$0.02, exp 31 December 2016

As announced the company intends to -

- → Raise \$15 million and re-comply with ASX Listing Rules Chapters 1 & 2
- → Issue 75 million shares via capital raise plus 28.5 million shares and 15 million options for acquisitions



Capital Mining Snapshot

CMY intends to become Australia's first listed company with a direct stake in a revenue producing Canadian Marijuana for Medical Purposes Regulations (MMPR) licensed company through its proposed investment in Broken Coast Cannabis Ltd.


Further to this, CMY intends to purchase 100% of licensing company Cannan Growers Inc. to facilitate future applications for global licenses if, when and where legislation changes.

To become a fully integrated cannabis company, CMY intends to also purchase 100% of Nutrawerx Inc., a company focused on developing branded retail hemp based products.

Most significantly, along with the Nutrawerx acquisition Michael Sautman an industry renowned, internationally regarded cannabis expert, is proposed to become Managing Director of CMY.



CMY Investment Proposition





Turnkey Expertise

Production & Distribution

Broken Coast Cannabis Ltd is a licensed medical cannabis company producing and distributing licensed product in Canada.

• Scientific Research and Product Development

Nutrawerx Inc. is a core science based company with an exclusive agreement to develop hemp based alternative products for mainstream US retailers with Marketing Management Inc. (MMI).

Licensing and Legislature IP

Cannan Growers Inc. has a proven QA/QC model to use as a Master Drug File to enable swift applications for international licenses if, where and when they become available.

Industry Renowned Personnel

A core team of experts with synergistic backgrounds and expertise across the international multi-billion dollar medical cannabis market.




Market Analysis

Medical Cannabis Industrial Hemp





Global Medical Cannabis Market





https://mmj business daily.com/wp-content/uploads/2014/06/Factbook 2014 Executive Summary.pdf and the summary of the summary

http://www.mpp.org/states/medical-marijuana-patient.html

http://www.independent.co.uk/news/world/asia/as-cannabis-is-widely-legalised-china-cashes-in-on-an-unprecedented-boom-9039191.html

http://www.cbc.ca/news/canada/1-3b-medical-marijuana-free-market-coming-to-canada-1.1872652

http://medicalmarijuana.org/en/content/20-medical-marijuana-in-europe

Medical Cannabis: Canada

- In 2014, Health Canada introduced the Marijuana for Medical Purposes Regulations (MMPR) which allows for the production of cannabis for medical purposes by a limited number of commercial producers.
- MMPR requires all medical cannabis patients to purchase products only from these Licensed Producers (LPs).
- Broken Coast Cannabis holds one of only 16 MMPR licenses to cultivate, grow and sell medical cannabis to eligible people under the MMPR. The number of licenses is currently limited by Health Canada.
- Health Canada predicts the market will grow to 450,000 patients by 2024 and reach a market value exceeding C\$1.3 billion.²



2 http://www.cbc.ca/news/canada/1-3b-medical-marijuana-free-market-coming-to-canada-1.1872652



Industrial Hemp

With no known allergens and gluten-free, hemp is an ideal, non-dairy alternative for vegetarian, vegan and raw diets.

- Hemp is a variety of Cannabis Sativa and of the same plant species as Medical Marijuana.
 It is genetically different to medical-grade cannabis as distinguished by its chemical makeup
- Industrial hemp refers to cannabis varieties that are primarily grown as an agricultural crop for food, textile and industrial applications
- Hemp plants are low in THC, the primary psychoactive chemical in medical cannabis and generally less than 1%. Industrial hemp usually has a THC quantity less than 0.3%. Medical Cannabis generally has THC levels of 10% and above
- Hemp is considered the answer to the health concerns linked to the soy market²



^{2.} http://www.huffingtonpost.com/dr-mercola/soy-health b 1822466.html



Industrial Hemp Market: USA

Hemp based food, cosmetic and nutritional supplement product market currently valued at US\$620 million market, which grew 21.2% last year ¹

- United States Federal legislation sets a ceiling of 0.3% for a cannabis variety to be identified as hemp and excluded from marijuana legislation.²
- In the United States there is no commercial industrial hemp production and the market is dependent on imports, both as finished retail products and as unprocessed ingredients.
- Canada, Germany, England and France are the leading hemp-producing nations.




^{1.} http://thehia.org/PR/2015-03-12-PR-2014-Annual-Retail-Sales-for-Hemp-Products-Estimated-at-\$620-Million.html?utm_source=HIA+PR%3A+2014+Hemp+Product+Sales+Est.+%24620+Million&utm_campaign=PR-2014-hemp-sales&utm_medium=email

^{2.} http://www.votehemp.com/2014_farm_bill_section_7606.html

^{3.} http://www.agmrc.org/commodities__products/fiber/industrial-hemp-profile/

Industrial Hemp






Capturing a Market

Broken Coast Cannabis Ltd Nutrawerx Inc. Cannan Growers Inc.




CMY Value Proposition





Broken Coast Cannabis (BCC)





BCC Production Expertise

CMY to purchase up to a 49% interest in BCC, subject to agreement

Licensing

- Health Canada awarded BCC a MMPR Medical Cannabis License October 2014 an achievement based on their capabilities to produce a high-grade product with consistent THC content
- BCC facility is strategically located in Duncan, British Columbia, a pro-cannabis region with capacity for growth

Production

- Production capacity currently 720,000 grams annually
- Standardized Operating Procedures for high quality, salable product
- 100% hydroponically grown in Custom built, single strain, lab-grade growing rooms

Distribution

- Currently distributing to 300 customers
- Wholesale contracts arranged with peer MMPR LPs to keep up with growing market demand representing 30% of total production currently
- BCC is receiving between C\$7 to \$9 per gram when sold to retail patients



BCC Production Expertise

State of the art techniques resulting in world class product of small batch, high quality cannabis







BCC Plans

- BCC currently occupies three units (approximately 13,000 sq ft) of a 10 unit industrial facility
- BCC has a lease in place for three additional units to increase the production area to 26,000 sqft
- The expansion is anticipated to boost eventual production by year end to 150,000 grams 170,000 grams per month fulfilling a mix of retail and wholesale clients.
- Increased efficiency and new economies of scale is expected to decrease production costs.
- Production improvements are anticipated to increase the average cannabinoid content of its products.





BCC Existing Product Suite and Specifications

Broken Coast branded MMPR Medical Grade Cannabis produced and distributed directly to registered patients





THC: 12-22% | CBD: <0.05% CBN: 1% 80% Indica 20% Sativa



Lasqueti – "God Kush"

THC: 12-22% | CBD: <0.05% CBN: 1.06% 80% Indica 20% Sativa



Texada – "Super Lemon Haze"

THC: 14-22% | CBD: TBA CBN: TBA 80% Indica 20% Sativa




Saturna – "Purple Lightning"

THC: 13-18% | CBD: <0.05% | CBN: 1% 60% Indica 40% Sativa



Nutrawerx Inc.





Nutrawerx Development IP

- Nutrawerx is a science driven, Colorado-based, corporation focusing on cannabis research and derivative product development.
- The company places an emphasis on unlocking the therapeutic potential of cannabinoids, with a focus on cannabidiol, or CBD.
- Nutrawerx has proven expertise in developing mainstream, pharmaceutical-grade,
 GMP, FDA, and ISO compliant hemp supplements.



Nutrawerx Joint Venture

Nutrawerx has entered into joint venture agreement with Marketing Management Inc (MMI) to develop branded mainstream hemp products for the rapidly expanding retail market

- MMI is the second largest private label food brokerage and marketing company in the United States providing concept-to-consumer services for the development of private and national brands.
- MMI has a comprehensive list of multibillion-dollar, high profile distribution companies. 1



Product Development


Alongside MMI, Nutrawerx is aiming to achieve a projected prominent market share.

Prototypes of a robust category list may be available to present to customers during the second quarter of 2015 including:

- Hulled seeds (nuts)
- Protein powders
- Meat substitutes
- Oil and butter
- Non-dairy beverages
- Cereals
- Snack bars
- Cosmetics
- Skin care items



Cannan Growers Inc. (CGI)





Cannan Growers Inc.

CGI are experts at compliant production methods for obtaining medical cannabis licensing

- CGI has a proven QA/QC model to use as a Drug Master File to enable swift applications for international licenses as and if they become available.
- They developed Standardised Operating Procedures (SOP) and proprietary extraction processes, designs and cannabinoid compounds to facilitate mass production of a consistent, pharmaceutical-grade product.
- These procedures assisted an MMPR licensed company in attaining their full growing and selling license.
- Cannan has an MMPR license application pending under the Cannan Grower's brand in relation to a facility located in North Saanich, Vancouver. Cannan has a long dated option to buy this facility for C\$1.2 million.
- CMY envisions using Cannan's IP and skill set to apply for one of Australia's first medical cannabis license if legislation permits. There is no current legislation allowing the sale or use of medical cannabis in Australia.



Renowned Personnel

Michael Sautman Tamar Wise Darwin Millard





Proposed Managing Director of CMY



Michael Sautman

Michael Sautman is an industry renowned medical cannabis expert. He has over 25 years of experience in natural product manufacturing.

As CEO of California Cashmere Co. Inc., (1990–2005) Sautman became a recognized expert in the production of rare animal fibre products including cashmere, silk and camel hair. He founded manufacturing operations in Mongolia, Tibet, China and the U.S.

Sautman then held the position of CEO of Bedrocan International, Inc.; a joint-venture with Bedrocan BV, the only licensed company in The Netherlands to grow cannabis for medicinal use by patients. He consulted with lawmakers and regulators in Canada, Israel and several U.S. states regarding the production and distribution of medical marijuana in The Netherlands. He initiated Bedrocan International's medical marijuana drug approval program with Health Canada, the Canadian Ministry of Health. Michael has a comprehensive understanding of cannabis legislation and manufacturing processes from around the world.

Before joining Nutrawerx, Michael was CEO of the Canadian Cannabis Research Institute Ltd. in Victoria, B.C. Sautman is a graduate of U.C. Berkeley, and holds a Master's Degree in International Administration from The School for International Training located in Vermont.



Proposed Chief Science Officer of CMY



Tamar Wise, B.Chem, MCDB

Tamar Wise was the Head of Science at Dixie Botanicals, formerly part of Dixie Elixirs, a leading producer of cannabis infused, lab tested products in the U.S. At Dixie Botanicals, Tamar led the formulation of medicine delivery systems and oversaw the scientific education outreach program.

As an early member of Colorado's Medical Marijuana Enforcement Division's Lab Rules and Regulations Committee, Wise has been an active participant in the state's evolving legislation. Currently, Wise is involved in leading the Hemp Industries Association Cannabinoid Committee. This committee is actively shaping and advising the evolving legislation and regulations surrounding cannabinoid therapies state by state and nationally.

Wise has a dual degree from the University of Colorado in Biochemistry and Molecular, Cellular and Developmental Biology. Her specialty is in formulation of natural nutraceuticals from *Cannabis* for use in proactive preventative care and overall wellness.



Proposed CMY Chief of Extraction Engineering



Darwin Millard, ME, Ex. E

Darwin Millard was a key member of the Science Division at Dixie Botanicals with responsibility for extraction methods and Standardized Operating Procedures. Millard was an important part of the team that developed and introduced the first hemp-based cannabinoid dietary supplement products onto the world market.

Millard is a strong proponent of cannabinoid-based treatment therapies as a replacement for pharmaceutical drugs. Through Nutrawerx, his efforts are directed towards developing commercially viable extraction methods for utilizing supercritical CO2 in the isolation of mono-specific cannabinoids from non-psychoactive varieties of cannabis, aka Hemp.

Millard has a degree in Mechanical Engineering and specializes in mechanical and solvent-based extraction methodologies for isolating highly volatile terpenophenolic secondary metabolites from botanicals. He has spent the last eight years focusing on the extraction of cannabinoids and other molecular constituents from the Cannabis plant.



Current Board of Directors

Dr James Ellingford - Non-Executive Director

Dr Ellingford holds a Post Graduate in Corporate Management, a Masters in Business Administration as well as a Doctorate in Management. Dr Ellingford also lecturers MBA students in Corporate Governance at a leading Sydney University and has a keen interest in ethics and governance. Formerly President of an international publicly listed multi-billion dollar business with its headquarters in Geneva, Switzerland and New York, USA.

Mr Robert McCauley - Executive Director

Robert McCauley is a Chartered Surveyor and Management Consultant with over 37 years experience in the mining, engineering and construction industries. Over the past 7 years Mr McCauley has been engaged in senior management roles for ASX listed companies.

Over the previous 30 years Mr McCauley has been involved in planning and infrastructure development of major mining and engineering projects with companies such as Worsley Alumina, Sir Alexander Gibb & Partners (UK), BHP and Boral including the Boddington Gold Mine WA; Monasavu Hydro Electric Scheme, Fiji and the North West Shelf Liquefied Natural Gas Project WA.



Current Board of Directors

Mr Peter Torney - Non-Executive Director

Mr Torney is a stockbroker with over 10 years' experience in the Australian financial services industry during which time he has been involved in a number of successful stockbroking & equity capital markets businesses. Prior to entering the Equity market Mr Torney has been involved in the advertising, real estate, finance, publishing & beef cattle production industries.

Mrs Elizabeth Hunt - Company Secretary

Elizabeth has over fifteen years' corporate and accounting experience with a particular interest in governance. Elizabeth's knowledge includes IPO management, governance & risk, company secretarial matters, ASX listing requirements, ASIC and other statutory reporting requirements, and financial accounting and reporting.

Elizabeth holds a BSc degree in Sustainable Development and has completed a Master of Accounting, the Governance Institute of Australia Certificate in Governance and Risk Management, and is a Graduate of the Australian Institute of Company Directors.



Industry Comparables



Industry Comparables

Company	Ticker	Description
CannaVest (US focused)	CANV - OTC	 Market Cap of US\$1 billion U.S based, creates products that are infused with cannabidiol (CBD)
Privateer Holdings (MMPR producer and seller)		 Private Equity with over \$500 million raised, investors include Peter Thiel Owner of Tilray, Canada's largest MMPR licensed producer Owner of leafly.com
Tweed Inc. (MMPR producer and seller)	TWD – TSX V	 Market Cap of C\$100 million Market Leading listed producer in Canada, Previous Quarter's revenue C\$641,309; Previous year revenue of CA \$1,145,662
Cannabis Satvia (US focused)	CBDS — OTC	 Market Cap of US\$85 million Developing product line of ready to eat Cannabis based products No current sales.
Mettrum (MMPR producer and seller)	MT – TSX-V	 Market Cap of C\$70 million MMPR licensed producer and seller based in Ontario Q3 results, \$689k in revs with \$1.3 million in losses 2,200 current retail clients

